Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abdel-Rahman, 2016, Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis, Ther. Adv. Respir. Dis., 10, 183, 10.1177/1753465816636557
Abu Samra, 2016, A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab, Eur. J. Ophthalmol., 26, e46, 10.5301/ejo.5000724
Ahmad, 2012, Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma, J. Oncol. Pharm. Pract., 18, 287, 10.1177/1078155211411001
Akhtari, 2009, Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 Antibody), J. Immunother., 32, 322, 10.1097/CJI.0b013e31819aa40b
Albarel, 2015, Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma, Eur. J. Endocrinol., 172, 195, 10.1530/EJE-14-0845
Armand, 2013, Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial, J. Clin. Oncol., 31, 4199, 10.1200/JCO.2012.48.3685
Arriola, 2016, Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC, J. Thor. Oncol., 11, 1511, 10.1016/j.jtho.2016.05.028
Attia, 2005, Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4, J. Clin. Oncol., 23, 6043, 10.1200/JCO.2005.06.205
Barjaktarevic, 2013, Organizing pneumonia as a side effect of ipilimumab treatment of melanoma, Chest, 143, 858, 10.1378/chest.12-1467
Berger, 2008, Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies, Clin. Cancer Res., 14, 3044, 10.1158/1078-0432.CCR-07-4079
Berman, 2010, Blockade of cytotoxic T-lymphocyte antigen- 4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma, Cancer Immun., 10, 11
Berthod, 2012, Pulmonary sarcoid-like granulomatosis induced by ipilimumab, J. Clin. Oncol., 30, e156, 10.1200/JCO.2011.39.3298
Bilen, 2016, Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody, J. Immunother Cancer, 4, 36, 10.1186/s40425-016-0139-8
Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643
Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627
Calabro, 2015, Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study, Lancet Respir Med., 3, 301, 10.1016/S2213-2600(15)00092-2
Callahan, 2011, Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis, J. Clin. Oncol., 2505, 10.1200/jco.2011.29.15_suppl.2505
Cappelli, 2017, Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab, Ann. Rheum. Dis., 76, 43, 10.1136/annrheumdis-2016-209595
Corsello, 2013, Endocrine side effects induced by immune checkpoint inhibitors, J. Clin. Endocrinol. Metab., 98, 1361, 10.1210/jc.2012-4075
Cortazar, 2016, Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors, Kidney Int., 90, 638, 10.1016/j.kint.2016.04.008
Cousin, 2016, Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities, Clin. Cancer Res., 22, 4550, 10.1158/1078-0432.CCR-15-2569
de Maleissye, 2016, Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy, N. Engl. J. Med., 375, 296, 10.1056/NEJMc1515584
Du-Thanh, 2015, Clostridium difficile infection may loom behind ipilimumab-induced auto-immune colitis, Eur. J. Dermatol., 25, 344, 10.1684/ejd.2015.2561
Eggermont, 2016, Prolonged survival in stage III Melanoma with Ipilimumab adjuvant therapy, N. Engl. J. Med., 375, 1845, 10.1056/NEJMoa1611299
Eggermont, 2015, Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial, Lancet Oncol., 16, 522, 10.1016/S1470-2045(15)70122-1
Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, 387, 1837, 10.1016/S0140-6736(16)00587
Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N. Engl. J. Med., 375, 1856, 10.1056/NEJMoa1602252
Gangadhar, 2014, Mitigating the toxic effects of anticancer immunotherapy, Nat. Rev. Clin. Oncol., 11, 91, 10.1038/nrclinonc.2013.245
Garon, 2015, Pembrolizumab for the treatment of non–small-cell lung cancer, N. Engl. J. Med., 372, 2018, 10.1056/NEJMoa1501824
Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N. Engl. J. Med., 369, 134, 10.1056/NEJMoa1305133
Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7
Hodi, 2014, Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial, JAMA, 312, 1744, 10.1001/jama.2014.13943
Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466
Horvat, 2015, Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center, J. Clin. Oncol., 33, 3193, 10.1200/jco.2015.60.8448
Huillard, 2014, Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review, Eur. Cancer J., 50, 638, 10.1016/j.ejca.2013.10.016
Ibrahim, 2011, Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma, J. Clin. Oncol, 10.1200/jco.2011.29.15_suppl.8583
Izzedine, 2014, Kidney injuries related to ipilimumab, Invest. New Drugs, 32, 769, 10.1007/s10637-014-0092-7
Jaber, 2006, Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent, Arch. Dermatol., 142, 166, 10.1001/archderm.142.2.166
Johncilla, 2015, Ipilimumab-associated Hepatitis: Clinico pathologic Characterization in a Series of 11 Cases, Am. J. Surg. Pathol., 39, 1075, 10.1097/PAS.0000000000000453
Johnson, 2015, Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune, JAMA Oncol., 2, 234, 10.1001/jamaoncol.2015.4368
Kindler, 2016, Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study, J. Clin. Oncol., 34
Kong, 2016, Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma, Melanoma Res., 26, 202, 10.1097/CMR.0000000000000232
Langer, 2015, Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors, Am. J. Clin. Oncol., 38, 422, 10.1097/coc.0000000000000059
Larkin, 2015, Combined nivolumab and ipilimumab or Monotherapy in Untreated Melanoma, N. Engl. J. Med., 373, 23, 10.1056/NEJMoa1504030
Liao, 2014, Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma, Neuro-oncology, 16, 589, 10.1093/neuonc/nou001
Massard, 2016, Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer, J. Clin. Oncol., 34, 3119, 10.1200/JCO.2016.67.9761
Maur, 2012, Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma, J. Clin. Oncol., 30, e76, 10.1200/JCO.2011.38.7886
Min, 2015, Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study, Clin. Cancer Res., 21, 749, 10.1158/1078-0432.CCR-14-2353
Minor, 2009, Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis, Cancer Biother. Radiopharm., 24, 321, 10.1089/cbr.2008.0607
Momtaz, 2015, Safety of Infusing ipilimumab Over 30 Minutes, J. Clin. Oncol., 33, 3454, 10.1200/JCO.2015.61.0030
Naidoo, 2015, Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann. Oncol., 26, 2375, 10.1093/annonc/mdv383
Nanda, 2016, Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study, J. Clin. Oncol., 34, 2460, 10.1200/JCO.2015.64.8931
Common Terminology Criteria for Adverse Events (CTCAE) v4.0.2009
Oble, 2008, Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis, Am. J. Surg. Pathol., 32, 1130, 10.1097/PAS.0b013e31817150e3
Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N. Engl. J. Med., 372, 2006, 10.1056/NEJMoa1414428
Postow, 2016, Toxicities associated with checkpoint inhibitor immunotherapy, UpToDate
Reck, 2016, Pembrolizumab versus Chemotherapy for PD-L1–Positive non–small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774
Ribas, , Hepatotoxicity with combination of vemurafenib and ipilimumab, N. Engl. J. Med., 368, 1365, 10.1056/nejmc1302338
Ribas, , Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma, J. Clin. Oncol., 616
Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X
Rizvi, 2015, Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol., 16, 257, 10.1016/S1470-2045(15)70054-9
Robert, , Nivolumab in previously untreated melanoma without BRAF mutation, N. Engl. J. Med., 372, 320, 10.1056/NEJMoa1412082
Robert, , Pembrolizumab versus ipilimumab in advanced melanoma, N. Engl. J. Med., 372, 2521, 10.1056/NEJMoa1503093
Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N. Engl. J. Med., 364, 2517, 10.1056/NEJMoa1104621
Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4
Ryder, 2014, Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution, Endocr. Relat. Cancer, 21, 371, 10.1530/ERC-13-0499
Schindler, 2014, Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab, J. Clin. Oncol., 32, 5s, 10.1200/jco.2014.32.15_suppl.9096
Seiwert, 2016, Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial, Lancet Oncol., 17, 956, 10.1016/S1470-2045(16)30066-3
Shahabi, 2013, Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune- related gastrointestinal adverse events, J. Transl. Med., 11, 75, 10.1186/1479-5876-11-75
Tarhini, 2012, Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma, J. Clin. Oncol., 30, 322, 10.1200/JCO.2011.37.5394
Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med., 366, 2443, 10.1056/NEJMoa1200690
Topalian, 2014, Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J. Clin. Oncol., 32, 1020, 10.1200/JCO.2013.53.0105
Villadolid, 2015, Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities, Transl. Lung Cancer Res., 4, 560, 10.3978/j.issn.2218-6751.2015.06.06
Weber, 2009, Ipilimumab: Controversies in its development, utility, and autoimmune adverse events, Cancer Immunol. Immunother., 58, 823, 10.1007/s00262-008-0653-8
Weber, 2013, Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma, Cancer Immun., 13, 7
Weber, 2012, Practical Management of immune related adverse events from immune checkpoint protein antibodies for the oncologist, Am. Soc. Clin. Oncol. Educ. Book, 2012, 174, 10.14694/EdBook
Weber, 2013, Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma, J. Clin. Oncol., 31, 4311, 10.1200/jco.2013.51.4802
Weber, 2015, Toxicities of Immunotherapy for the Practitioner, J. Clin. Oncol., 10.1200/jco.2014.60.0379
Weber, 2009, A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma, Clin. Cancer Res., 15, 5591, 10.1158/1078-0432.CCR-09-1024
Westin, 2014, Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, Lancet Oncol., 15, 69, 10.1016/S1470-2045(13)70551-5
Wilgenhof, 2011, Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient, Ann. Oncol., 22, 991, 10.1093/annonc/mdr028
Williams, 2016, Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer, JAMA Neurol., 73, 928, 10.1001/jamaneurol.2016.1399